TW200635900A - Chemical compound and its use - Google Patents
Chemical compound and its useInfo
- Publication number
- TW200635900A TW200635900A TW094144588A TW94144588A TW200635900A TW 200635900 A TW200635900 A TW 200635900A TW 094144588 A TW094144588 A TW 094144588A TW 94144588 A TW94144588 A TW 94144588A TW 200635900 A TW200635900 A TW 200635900A
- Authority
- TW
- Taiwan
- Prior art keywords
- hyper
- chemical compound
- triglyceridaemias
- lipidaemias
- cholesterolamemias
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010021024 Hypolipidaemia Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 208000026621 hypolipoproteinemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004060997A DE102004060997A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| DE102004061000A DE102004061000A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200635900A true TW200635900A (en) | 2006-10-16 |
Family
ID=35841894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094144588A TW200635900A (en) | 2004-12-18 | 2005-12-16 | Chemical compound and its use |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8124775B2 (https=) |
| EP (1) | EP1828137B1 (https=) |
| JP (1) | JP5132317B2 (https=) |
| KR (1) | KR20070090248A (https=) |
| AR (1) | AR055011A1 (https=) |
| AT (1) | ATE555097T1 (https=) |
| AU (1) | AU2005315770B2 (https=) |
| BR (1) | BRPI0519602A2 (https=) |
| CA (1) | CA2591397A1 (https=) |
| CU (1) | CU23452B7 (https=) |
| CY (1) | CY1112887T1 (https=) |
| DK (1) | DK1828137T3 (https=) |
| DO (1) | DOP2005000259A (https=) |
| ES (1) | ES2384980T3 (https=) |
| GT (1) | GT200500377A (https=) |
| IL (1) | IL184008A (https=) |
| MA (1) | MA29100B1 (https=) |
| MX (1) | MX2007007188A (https=) |
| NO (1) | NO20073146L (https=) |
| PE (1) | PE20060767A1 (https=) |
| PL (1) | PL1828137T3 (https=) |
| PT (1) | PT1828137E (https=) |
| RU (1) | RU2393151C2 (https=) |
| SI (1) | SI1828137T1 (https=) |
| TW (1) | TW200635900A (https=) |
| UY (1) | UY29276A1 (https=) |
| WO (1) | WO2006063828A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0519566A2 (pt) * | 2004-12-18 | 2009-01-27 | Bayer Healthcare Ag | derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp |
| DE102006012548A1 (de) * | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| BRPI0909105A2 (pt) * | 2008-03-05 | 2015-08-25 | Boehringer Ingelheim Int | Derivados de piridina tricíclicos, composição farmacêutica e uso dos mesmos, bem como processos para preparar os ditos compostos e a dita composição farmacêutica |
| UY33229A (es) * | 2010-02-19 | 2011-09-30 | Boehringer Ingelheim Int | Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación |
| CA2804924C (en) * | 2010-07-09 | 2016-06-28 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| EP2675811A1 (en) | 2011-02-17 | 2013-12-25 | Boehringer Ingelheim International GmbH | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| EP2760868B1 (en) | 2011-08-17 | 2018-04-25 | Boehringer Ingelheim International GmbH | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
| TWI570118B (zh) | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
| MX384679B (es) | 2014-07-30 | 2025-03-14 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl). |
| WO2025185022A1 (zh) * | 2024-03-05 | 2025-09-12 | 维康平生(北京)生物科技有限公司 | 一种脂肪体的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128681A1 (de) * | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| MA24643A1 (fr) * | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| DE19741399A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| DE19935966A1 (de) | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| DE10250687A1 (de) | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
| BRPI0519566A2 (pt) * | 2004-12-18 | 2009-01-27 | Bayer Healthcare Ag | derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp |
-
2005
- 2005-12-15 ES ES05820528T patent/ES2384980T3/es not_active Expired - Lifetime
- 2005-12-15 PL PL05820528T patent/PL1828137T3/pl unknown
- 2005-12-15 EP EP05820528A patent/EP1828137B1/de not_active Expired - Lifetime
- 2005-12-15 WO PCT/EP2005/013490 patent/WO2006063828A1/de not_active Ceased
- 2005-12-15 SI SI200531547T patent/SI1828137T1/sl unknown
- 2005-12-15 CA CA002591397A patent/CA2591397A1/en not_active Abandoned
- 2005-12-15 AT AT05820528T patent/ATE555097T1/de active
- 2005-12-15 DK DK05820528.7T patent/DK1828137T3/da active
- 2005-12-15 AU AU2005315770A patent/AU2005315770B2/en not_active Ceased
- 2005-12-15 MX MX2007007188A patent/MX2007007188A/es active IP Right Grant
- 2005-12-15 RU RU2007127127/04A patent/RU2393151C2/ru not_active IP Right Cessation
- 2005-12-15 PT PT05820528T patent/PT1828137E/pt unknown
- 2005-12-15 JP JP2007545948A patent/JP5132317B2/ja not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519602-7A patent/BRPI0519602A2/pt not_active IP Right Cessation
- 2005-12-15 KR KR1020077016219A patent/KR20070090248A/ko not_active Ceased
- 2005-12-15 US US11/793,482 patent/US8124775B2/en not_active Expired - Fee Related
- 2005-12-16 PE PE2005001475A patent/PE20060767A1/es not_active Application Discontinuation
- 2005-12-16 DO DO2005P000259A patent/DOP2005000259A/es unknown
- 2005-12-16 AR ARP050105313A patent/AR055011A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144588A patent/TW200635900A/zh unknown
- 2005-12-19 GT GT200500377A patent/GT200500377A/es unknown
- 2005-12-20 UY UY29276A patent/UY29276A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 CU CU20070140A patent/CU23452B7/es not_active IP Right Cessation
- 2007-06-18 MA MA30003A patent/MA29100B1/fr unknown
- 2007-06-18 IL IL184008A patent/IL184008A/en not_active IP Right Cessation
- 2007-06-19 NO NO20073146A patent/NO20073146L/no not_active Application Discontinuation
-
2012
- 2012-02-16 US US13/398,290 patent/US20120142728A1/en not_active Abandoned
- 2012-06-29 CY CY20121100588T patent/CY1112887T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080255068A1 (en) | 2008-10-16 |
| US20120142728A1 (en) | 2012-06-07 |
| AU2005315770B2 (en) | 2011-12-08 |
| US8124775B2 (en) | 2012-02-28 |
| DOP2005000259A (es) | 2006-11-15 |
| IL184008A0 (en) | 2007-10-31 |
| PE20060767A1 (es) | 2006-09-10 |
| CA2591397A1 (en) | 2006-06-22 |
| RU2007127127A (ru) | 2009-01-27 |
| SI1828137T1 (sl) | 2012-08-31 |
| JP5132317B2 (ja) | 2013-01-30 |
| NO20073146L (no) | 2007-09-18 |
| AU2005315770A1 (en) | 2006-06-22 |
| IL184008A (en) | 2012-03-29 |
| ATE555097T1 (de) | 2012-05-15 |
| MA29100B1 (fr) | 2007-12-03 |
| EP1828137A1 (de) | 2007-09-05 |
| KR20070090248A (ko) | 2007-09-05 |
| UY29276A1 (es) | 2006-07-31 |
| PL1828137T3 (pl) | 2012-09-28 |
| DK1828137T3 (da) | 2012-07-23 |
| RU2393151C2 (ru) | 2010-06-27 |
| ES2384980T3 (es) | 2012-07-16 |
| GT200500377A (es) | 2006-11-09 |
| CY1112887T1 (el) | 2016-04-13 |
| MX2007007188A (es) | 2007-08-14 |
| EP1828137B1 (de) | 2012-04-25 |
| JP2008524145A (ja) | 2008-07-10 |
| BRPI0519602A2 (pt) | 2009-02-25 |
| CU23452B7 (es) | 2009-12-01 |
| PT1828137E (pt) | 2012-07-04 |
| WO2006063828A1 (de) | 2006-06-22 |
| AR055011A1 (es) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005058834A3 (en) | Quinolines useful in treating cardiovascular disease | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2005046603A3 (en) | Pyridine compounds | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| EP1633722A4 (en) | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | |
| MY142029A (en) | Phenoxyacetic acid derivatives | |
| MY150285A (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | |
| WO2006073973A3 (en) | Novel benzylamine derivatives as cetp inhibitors | |
| TW200505837A (en) | Novel compounds | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| MY139541A (en) | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | |
| WO2006122186A3 (en) | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| TW200612892A (en) | Novel compounds | |
| TW200509937A (en) | Novel compounds and their use in therapy | |
| TW200736213A (en) | Dicarboxylic acid derivatives and their use | |
| WO2004058174A3 (en) | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| TW200621690A (en) | Novel compounds | |
| WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| TW200621765A (en) | Substituted phenylaminothiazoles and their use | |
| WO2005070390A3 (en) | Mitratapide oral solution | |
| TW200635900A (en) | Chemical compound and its use | |
| WO2007109799A3 (en) | Polymorphs of eszopiclone malate | |
| GB0322510D0 (en) | Novel compounds |